Colgate-Palmolive (India) Ltd (CPIL) produces and distributes oral care products. The company's portfolio includes a wide range of products such as toothpastes, toothbrushes, mouthwashes & rinses, prescription products, specialty products, products for kids, and whitening kits. The benefits of these products include cavity prevention, enamel protection, fresh breath, plaque prevention, sensitivity relief, and tartar control. CPIL serves its customers through two brands Colgate and Palmolive. The company offers various products including colgate strong teeth, colgate diabetics, colgate total, colgate 360, colgate maxfresh, colgate sensitive original, colgate visible white, colgate kids and colgate keep.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CPIL continues to strengthen its R&D framework with a focus on revolutionizing oral, skin, and overall health as part of its 2025 strategy. The company aims to enhance its research capabilities by leveraging regional strengths and nurturing the growth of its core business in India. The Colgate Clinical Innovation Institute (CCII) at the IGTeD serves as a key initiative to drive healthcare innovation. CPIL has established a state-of-the-art research center in Mumbai, India, dedicated to advancing its innovation pipeline. Key product developments under this initiative include the Visible White O2 relaunch, MaxFresh variants, Colgate Strong Teeth relaunch, Colgate Total Sensitive, and the Palmolive Bodywash range. During the year, the company incurred an R&D expenditure of INR135 million (INR42.9 million capital and INR92.1 million recurring), which represented 24.7% of its total R&D and capital investments and approximately 0.24% of annual revenue.